| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
06-21-2013, 09:41 PM
|
#1 | |||
|
||||
|
Senior Member
|
Prof Finkelstein presented new data on the drug known as PBT434 at the 17th annual congress of Parkinson's Disease and Movement Disorders in Sydney this week.
He said in animal models the synthetic compound had prevented cell death by stopping destructive interactions in the brain between dopamine and iron. It also prevented the accumulation of alpha synuclein protein. "It has been designed to bind to iron, stopping it from interacting with the dopamine, which causes oxidative stress, and to stop alpha synuclein aggregating," Prof Finkelstein said. He said the next step would be to trial the drug in humans, which was expected to take place within two years... http://www.heraldsun.com.au/technolo...-1226667807638
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
|
 Reply With Quote
|
| "Thanks for this!" says: | Stand Tall (06-22-2013) |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Too much or too little alpha-synuclein | Parkinson's Disease | |||
| Alpha-synuclein | Parkinson's Disease | |||
| Alpha synuclein | Parkinson's Disease | |||
| Cell Death by Dopamine, Calcium and Alpha-synuclein: Q&A with Dr. David Sulzer | Parkinson's Disease | |||
drug stops iron interaction with dopamine and interrupts alpha synuclein aggregation
Threaded Mode